Platform Asset
Autism Spectrum Disorders
Key Facts
About Enthorin Therapeutics
Enthorin Therapeutics is a private, clinical-stage biotech based in Cambridge, USA, leveraging a circuit-based therapeutic approach for CNS disorders. The company's lead asset, ENT-3379 for Fragile X Syndrome, is being advanced through a significant partnership with Mirum Pharmaceuticals. Founded by seasoned drug developers and a leading clinical neuroscientist, Enthorin is positioned to address major gaps in the treatment of conditions like Fragile X, Autism Spectrum Disorders, and Parkinson's Disease.
View full company profileAbout Enthorin Therapeutics
Enthorin Therapeutics is a private, clinical-stage biotech based in Cambridge, USA, leveraging a circuit-based therapeutic approach for CNS disorders. The company's lead asset, ENT-3379 for Fragile X Syndrome, is being advanced through a significant partnership with Mirum Pharmaceuticals. Founded by seasoned drug developers and a leading clinical neuroscientist, Enthorin is positioned to address major gaps in the treatment of conditions like Fragile X, Autism Spectrum Disorders, and Parkinson's Disease.
View full company profileTherapeutic Areas
Other Autism Spectrum Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed ASD Program | Translation-X | Pre-clinical |